Fig. 6. Effects of twice daily treatments on growth and survival of CML cells derived from (A, B) patient 2, (C, D) patient 3 (E, F) healthy control individual of SpA4-anti-bcr (•), SpA4-(M5)anti-bcr (▪), SpA2-anti-bcr (▴), SpA4-anti-b3a2 (□), SpA4-anti-b2a2 (○), anti-b3a2 (▵), SpA4-(M6)anti-b3a2 (◊) or anti-bcr (⧫). ODNs were added twice daily at a concentration of 5 μmol/L. Data points are the ratio of the viable cell numbers for the treated and untreated cultures × 100. Experiments were performed in duplicate and results averaged.
Fig. 6.

Effects of twice daily treatments on growth and survival of CML cells derived from (A, B) patient 2, (C, D) patient 3 (E, F) healthy control individual of SpA4-anti-bcr (•), SpA4-(M5)anti-bcr (▪), SpA2-anti-bcr (▴), SpA4-anti-b3a2 (□), SpA4-anti-b2a2 (○), anti-b3a2 (▵), SpA4-(M6)anti-b3a2 (◊) or anti-bcr (⧫). ODNs were added twice daily at a concentration of 5 μmol/L. Data points are the ratio of the viable cell numbers for the treated and untreated cultures × 100. Experiments were performed in duplicate and results averaged.

or Create an Account

Close Modal
Close Modal